Hawaii Senate Bill SCR86

Hawaii 2023 Regular Session

• Introduced: 3/10/23
• Refer: 3/15/23

Caption

Recognizing And Supporting Ongoing Collaborative Efforts To Implement A Statewide Strategy To Eliminate Viral Hepatitis Types A, B, And C In Hawaii.

Impact

The resolution emphasizes that specific communities are at higher risk for developing viral hepatitis, including indigenous populations, Asian American and Pacific Islander communities, veterans, and the homeless. By supporting efforts such as expanding Med-QUEST to include hepatitis C medications and syringe service programs, the bill aims to reduce the incidence of these diseases among vulnerable groups. The overarching goal is to improve life expectancy for affected individuals, specifically addressing significant disparities that exist within Hawaiian society.

Summary

SCR86 is a Senate Concurrent Resolution recognizing and supporting ongoing collaborative efforts aimed at implementing a statewide strategy to eliminate viral hepatitis types A, B, and C in Hawaii. This bill highlights the severe public health implications of viral hepatitis, which has been linked to increased rates of cirrhosis and liver cancer in the state's population. Notably, the hepatitis B mortality rate in Hawaii exceeds the national average, signaling a critical need for focused health intervention strategies.

Contention

According to the resolution, continued coordination and implementation of the 2020-2030 Hep Free Hawaii strategy is essential to achieving the goal of eliminating viral hepatitis in the state. The strategy outlines priorities such as raising awareness, improving access to healthcare services, advocacy, and ensuring equity in health interventions. A joint informational briefing is proposed post-regular session to assess progress and recommend future legislative actions, highlighting the ongoing commitment to this public health imperative.